[
    {
        "id": 5193,
        "drug_name": "TRAZIMERA (Herceptin biosimilar)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Herceptin biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-15",
        "link": "https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2019\/US-FDA-Approves-Pfizers-Oncology-Biosimilar-TRAZIMERA-trastuzumab-qyyp-a-Biosimilar-to-Herceptin1\/default.aspx",
        "note": "FDA Approval March 11, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4643,
        "drug_name": "TECENTRIQ (atezolizumab) - IMpower133",
        "clinical_trial_id": "NCT02763579",
        "has_trial_insight_page": 0,
        "indication": "Squamous non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-18",
        "link": "https:\/\/www.roche.com\/investors\/updates\/inv-update-2019-03-19.htm",
        "note": "FDA approval announced March 18, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2599,
        "drug_name": "ZULRESSO (brexanolone) - SAGE-547 (202C)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Postpartum Depression - moderate",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-19",
        "link": "https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-fda-approval-zulressotm-brexanolone",
        "note": "FDA approval announced March 19, 2018.",
        "company_entity_id": 273,
        "company_ticker": "SAGE",
        "company_name": "Sage Therapeutics Inc.",
        "company_price": "20.3500",
        "company_change": -0.83,
        "company_percent_change": -3.92,
        "company_optionable": 1,
        "company_number_of_shares": 60106687,
        "price_change_sparkline": [
            [
                25.64,
                1706677200
            ],
            [
                26,
                1706763600
            ],
            [
                24.77,
                1706850000
            ],
            [
                24.27,
                1707109200
            ],
            [
                24.72,
                1707195600
            ],
            [
                23.91,
                1707282000
            ],
            [
                23.78,
                1707368400
            ],
            [
                23.69,
                1707454800
            ],
            [
                23.83,
                1707714000
            ],
            [
                23.02,
                1707800400
            ],
            [
                25.75,
                1707886800
            ],
            [
                25.41,
                1707973200
            ],
            [
                23.27,
                1708059600
            ],
            [
                22.17,
                1708405200
            ],
            [
                22.2,
                1708491600
            ],
            [
                22.25,
                1708578000
            ],
            [
                22.01,
                1708664400
            ],
            [
                22.63,
                1708923600
            ],
            [
                22.71,
                1709010000
            ],
            [
                22.55,
                1709096400
            ],
            [
                21.48,
                1709182800
            ],
            [
                21.86,
                1709269200
            ],
            [
                21.77,
                1709528400
            ],
            [
                21.23,
                1709614800
            ],
            [
                21.13,
                1709701200
            ],
            [
                21.37,
                1709787600
            ],
            [
                22.09,
                1709874000
            ],
            [
                21.18,
                1710129600
            ],
            [
                20.35,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2599,
        "drug_name": "ZULRESSO (brexanolone) - SAGE-547 (202C)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Postpartum Depression - moderate",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-19",
        "link": "https:\/\/investor.sagerx.com\/news-releases\/news-release-details\/sage-therapeutics-announces-fda-approval-zulressotm-brexanolone",
        "note": "FDA approval announced March 19, 2018.",
        "company_entity_id": 627,
        "company_ticker": "LGND",
        "company_name": "Ligand Pharmaceuticals Incorporated",
        "company_price": "72.3600",
        "company_change": 0.11,
        "company_percent_change": 0.15,
        "company_optionable": 1,
        "company_number_of_shares": 17705287,
        "price_change_sparkline": [
            [
                73.1,
                1706677200
            ],
            [
                74.17,
                1706763600
            ],
            [
                74.54,
                1706850000
            ],
            [
                74.72,
                1707109200
            ],
            [
                75.31,
                1707195600
            ],
            [
                74.51,
                1707282000
            ],
            [
                75.41,
                1707368400
            ],
            [
                75.88,
                1707454800
            ],
            [
                75.64,
                1707714000
            ],
            [
                71,
                1707800400
            ],
            [
                73.62,
                1707886800
            ],
            [
                74.65,
                1707973200
            ],
            [
                73.66,
                1708059600
            ],
            [
                72.37,
                1708405200
            ],
            [
                72.67,
                1708491600
            ],
            [
                73.56,
                1708578000
            ],
            [
                75.87,
                1708664400
            ],
            [
                74.42,
                1708923600
            ],
            [
                89.2,
                1709010000
            ],
            [
                84.35,
                1709096400
            ],
            [
                79.35,
                1709182800
            ],
            [
                78.7,
                1709269200
            ],
            [
                76.28,
                1709528400
            ],
            [
                74,
                1709614800
            ],
            [
                72.71,
                1709701200
            ],
            [
                72.47,
                1709787600
            ],
            [
                73.77,
                1709874000
            ],
            [
                72.25,
                1710129600
            ],
            [
                72.36,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2888,
        "drug_name": "SUNOSI (solriamfetol)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Excessive sleepiness associated with narcolepsy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-20",
        "link": "http:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-sunositm",
        "note": "FDA Approval announced March 20, 2019.",
        "company_entity_id": 381,
        "company_ticker": "JAZZ",
        "company_name": "Jazz Pharmaceuticals plc",
        "company_price": "115.7900",
        "company_change": -0.84,
        "company_percent_change": -0.72,
        "company_optionable": 1,
        "company_number_of_shares": 62345283,
        "price_change_sparkline": [
            [
                122.72,
                1706677200
            ],
            [
                123.68,
                1706763600
            ],
            [
                122.9,
                1706850000
            ],
            [
                121.98,
                1707109200
            ],
            [
                124.71,
                1707195600
            ],
            [
                122.94,
                1707282000
            ],
            [
                122.67,
                1707368400
            ],
            [
                123.43,
                1707454800
            ],
            [
                124.24,
                1707714000
            ],
            [
                121.83,
                1707800400
            ],
            [
                122.24,
                1707886800
            ],
            [
                126.82,
                1707973200
            ],
            [
                126.78,
                1708059600
            ],
            [
                126.36,
                1708405200
            ],
            [
                128.42,
                1708491600
            ],
            [
                128.45,
                1708578000
            ],
            [
                132.28,
                1708664400
            ],
            [
                132.77,
                1708923600
            ],
            [
                132.26,
                1709010000
            ],
            [
                129.7,
                1709096400
            ],
            [
                118.9,
                1709182800
            ],
            [
                118.85,
                1709269200
            ],
            [
                117.53,
                1709528400
            ],
            [
                118.42,
                1709614800
            ],
            [
                117.19,
                1709701200
            ],
            [
                116.37,
                1709787600
            ],
            [
                117.53,
                1709874000
            ],
            [
                116.63,
                1710129600
            ],
            [
                115.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5011,
        "drug_name": "MAYZENT (siponimod)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Secondary progressive multiple sclerosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-03-26",
        "link": "http:\/\/hugin.info\/134323\/R\/2239762\/882918.pdf",
        "note": "FDA approval announced March 26, 2019.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5645,
        "drug_name": "IBRANCE (palbociclib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HR+\/HER2- advanced breast cancer in men",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-04",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer",
        "note": "FDA approval of sNDA announced April 4, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2894,
        "drug_name": "DOVATO (Dolutegravir and lamivudine)",
        "clinical_trial_id": "NCT02831673",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-08",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-na%C3%AFve-hiv-1-adults\/",
        "note": "FDA approval announced April 8, 2019.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2999,
        "drug_name": "EVENITY (Romosozumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Osteoporosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-09",
        "link": "http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=RssLanding&cat=news&id=2394009",
        "note": "FDA Approval announced April 9, 2019.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4627,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "NCT02220894",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-11",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-Expanded-Monotherapy-Label-for-Mercks-KEYTRUDA-pembrolizumab\/default.aspx",
        "note": "FDA Approval announced April 11, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4455,
        "drug_name": "BALVERSA (erdafitinib)",
        "clinical_trial_id": "NCT02365597",
        "has_trial_insight_page": 0,
        "indication": "Urothelial cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-12",
        "link": "http:\/\/johnsonandjohnson.gcs-web.com\/news-releases\/news-release-details\/balversatm-erdafitinib-receives-us-fda-approval-treatment",
        "note": "FDA Approval announced April 12, 2019.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5158,
        "drug_name": "KEYTRUDA (pembrolizumab)and  INLYTA (axitinib)",
        "clinical_trial_id": "NCT02853331",
        "has_trial_insight_page": 0,
        "indication": "Renal cell carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-22",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-in-Combination-With-Inlyta-axitinib-as-First-Line-Treatment-for-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC\/default.aspx",
        "note": "FDA approval announced April 22, 2019.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5158,
        "drug_name": "KEYTRUDA (pembrolizumab)and  INLYTA (axitinib)",
        "clinical_trial_id": "NCT02853331",
        "has_trial_insight_page": 0,
        "indication": "Renal cell carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-22",
        "link": "https:\/\/investors.merck.com\/news\/press-release-details\/2019\/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-in-Combination-With-Inlyta-axitinib-as-First-Line-Treatment-for-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC\/default.aspx",
        "note": "FDA approval announced April 22, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3023,
        "drug_name": "SKYRIZI (risankizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Psoriasis ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-23",
        "link": "https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-expands-immunology-portfolio-in-us-with-fda-approval-skyrizi-risankizumab-rzaa-for-moderate-to-severe-plaque-psoriasis.htm",
        "note": "FDA approval announced April 23, 2019.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2780,
        "drug_name": "DUOBRII (halobetasol propionate and tazarotene)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Psoriasis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-25",
        "link": "https:\/\/ir.bauschhealth.com\/tools\/viewpdf.aspx?page={861A1E11-4FC9-4A8D-9E84-AD2F996900A4}",
        "note": "FDA approval announced April 25, 2019.",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2770,
        "drug_name": "PRALUENT (alirocumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cardiovascular events",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-26",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-praluentr-alirocumab-prevent-heart-attack-stroke",
        "note": "FDA approval announced April 26, 2019.",
        "company_entity_id": 388,
        "company_ticker": "REGN",
        "company_name": "Regeneron Pharmaceuticals Inc.",
        "company_price": "970.5700",
        "company_change": 6.13,
        "company_percent_change": 0.64,
        "company_optionable": 1,
        "company_number_of_shares": 109761896,
        "price_change_sparkline": [
            [
                942.78,
                1706677200
            ],
            [
                957.78,
                1706763600
            ],
            [
                945.18,
                1706850000
            ],
            [
                936.33,
                1707109200
            ],
            [
                937.81,
                1707195600
            ],
            [
                938.49,
                1707282000
            ],
            [
                946.43,
                1707368400
            ],
            [
                953.42,
                1707454800
            ],
            [
                947.06,
                1707714000
            ],
            [
                940.48,
                1707800400
            ],
            [
                947.82,
                1707886800
            ],
            [
                954.73,
                1707973200
            ],
            [
                948.05,
                1708059600
            ],
            [
                946.87,
                1708405200
            ],
            [
                952.84,
                1708491600
            ],
            [
                964.89,
                1708578000
            ],
            [
                981.2,
                1708664400
            ],
            [
                989.28,
                1708923600
            ],
            [
                993.35,
                1709010000
            ],
            [
                987.61,
                1709096400
            ],
            [
                966.09,
                1709182800
            ],
            [
                982.82,
                1709269200
            ],
            [
                971.19,
                1709528400
            ],
            [
                965.21,
                1709614800
            ],
            [
                972.1,
                1709701200
            ],
            [
                973.31,
                1709787600
            ],
            [
                968.83,
                1709874000
            ],
            [
                964.44,
                1710129600
            ],
            [
                970.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2770,
        "drug_name": "PRALUENT (alirocumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cardiovascular events",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-26",
        "link": "https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/fda-approves-praluentr-alirocumab-prevent-heart-attack-stroke",
        "note": "FDA approval announced April 26, 2019.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5034,
        "drug_name": "KALYDECO (ivacaftor)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cystic Fibrosis (6-12 mths)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-04-30",
        "link": "https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/fda-approves-kalydecor-ivacaftor-first-and-only-cftr-modulator",
        "note": "FDA Approval announced April 30, 2019.",
        "company_entity_id": 306,
        "company_ticker": "VRTX",
        "company_name": "Vertex Pharmaceuticals Incorporated",
        "company_price": "412.4500",
        "company_change": -2.02,
        "company_percent_change": -0.49,
        "company_optionable": 1,
        "company_number_of_shares": 258307816,
        "price_change_sparkline": [
            [
                433.38,
                1706677200
            ],
            [
                433.87,
                1706763600
            ],
            [
                424.68,
                1706850000
            ],
            [
                428.89,
                1707109200
            ],
            [
                416.13,
                1707195600
            ],
            [
                419.08,
                1707282000
            ],
            [
                423.06,
                1707368400
            ],
            [
                422.91,
                1707454800
            ],
            [
                418.53,
                1707714000
            ],
            [
                416.04,
                1707800400
            ],
            [
                417.88,
                1707886800
            ],
            [
                426.29,
                1707973200
            ],
            [
                422.2,
                1708059600
            ],
            [
                420.64,
                1708405200
            ],
            [
                419.63,
                1708491600
            ],
            [
                426.78,
                1708578000
            ],
            [
                430.11,
                1708664400
            ],
            [
                433.48,
                1708923600
            ],
            [
                430.92,
                1709010000
            ],
            [
                426.97,
                1709096400
            ],
            [
                420.74,
                1709182800
            ],
            [
                432.76,
                1709269200
            ],
            [
                424.03,
                1709528400
            ],
            [
                415.44,
                1709614800
            ],
            [
                411.85,
                1709701200
            ],
            [
                410.54,
                1709787600
            ],
            [
                413.59,
                1709874000
            ],
            [
                414.47,
                1710129600
            ],
            [
                412.45,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5199,
        "drug_name": "DENGVAXIA (CYD-TDV)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Dengue",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-01",
        "link": "http:\/\/www.news.sanofi.us\/2019-05-01-FDA-approves-Dengvaxia-R-for-the-prevention-of-dengue-in-individuals-ages-9-through-16-living-in-U-S-endemic-areas",
        "note": "FDA approval announced May 1, 2019.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5214,
        "drug_name": "TIBSOVO (ivosidenib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Frontline AML with IDH1 mutation",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-02",
        "link": "https:\/\/agiospharmaceuticalsinc.gcs-web.com\/news-releases\/news-release-details\/agios-announces-fda-approval-supplemental-new-drug-application",
        "note": "FDA Approval announced May 2, 2019.",
        "company_entity_id": 23,
        "company_ticker": "AGIO",
        "company_name": "Agios Pharmaceuticals Inc.",
        "company_price": "30.2900",
        "company_change": -0.51,
        "company_percent_change": -1.66,
        "company_optionable": 1,
        "company_number_of_shares": 56194847,
        "price_change_sparkline": [
            [
                22.62,
                1706677200
            ],
            [
                22.96,
                1706763600
            ],
            [
                23.09,
                1706850000
            ],
            [
                23.73,
                1707109200
            ],
            [
                24.15,
                1707195600
            ],
            [
                23.69,
                1707282000
            ],
            [
                24.18,
                1707368400
            ],
            [
                25.14,
                1707454800
            ],
            [
                25.88,
                1707714000
            ],
            [
                25.15,
                1707800400
            ],
            [
                25.9,
                1707886800
            ],
            [
                26.8,
                1707973200
            ],
            [
                26.51,
                1708059600
            ],
            [
                27.1,
                1708405200
            ],
            [
                26.8,
                1708491600
            ],
            [
                29.78,
                1708578000
            ],
            [
                32.99,
                1708664400
            ],
            [
                32.87,
                1708923600
            ],
            [
                34.81,
                1709010000
            ],
            [
                33.67,
                1709096400
            ],
            [
                32.32,
                1709182800
            ],
            [
                32.27,
                1709269200
            ],
            [
                32.17,
                1709528400
            ],
            [
                31.37,
                1709614800
            ],
            [
                31.79,
                1709701200
            ],
            [
                31.37,
                1709787600
            ],
            [
                31.29,
                1709874000
            ],
            [
                30.8,
                1710129600
            ],
            [
                30.29,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5738,
        "drug_name": "Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Type 2 diabetes",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-03",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/qternmet-xr-approved-in-the-us-for-the-treatment-of-type-2-diabetes-03052019.html",
        "note": "FDA approval announced May 3, 2019.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3576,
        "drug_name": "KADCYLA (trastuzumab emtansine)",
        "clinical_trial_id": "NCT01772472",
        "has_trial_insight_page": 0,
        "indication": "HER2-positive breast cancer - residual invasive disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-06",
        "link": "https:\/\/www.roche.com\/media\/releases\/med-cor-2019-05-06.htm",
        "note": "FDA approval announced May 6, 2019.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5409,
        "drug_name": "VYNDAQEL (tafamidis)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Transthyretin amyloid cardiomyopathy (ATTR-CM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-06",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease",
        "note": "FDA approval announced May 6, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4366,
        "drug_name": "VYNDAQEL (tafamidis)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Transthyretin amyloid cardiomyopathy (ATTR-CM)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2019-05-06",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease",
        "note": "FDA approval announced May 6, 2019.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    }
]